North America Migraine Drug Market

North America Migraine Drug Market Size (2022 to 2027)

The size of the Migraine Drug Market in North America is valued at USD 1.50 billion in 2022. This value is estimated to be growing at a CAGR of 3.98% to reach USD 1.82 billion by 2027.

Growing awareness of mental health disorders such as depression and stress is expected to boost the Migraine drug market growth in North America. Social elements such as economic stress, the partition of family-oriented supporting structures, exacerbating environmental conditions are further estimated to escalate the market growth during the review period. Increasing the necessity for migraine drugs, the attainability of research funds from private and public organizations, enhancement of reimbursement scenarios towards related medications is to propel the market growth. The invention of novel drugs and results related to the quick obtainment of new medicines is to surge the market growth during the assessment period. The rising attention of vendors on the developing markets is to fuel the market.

Side-effects related to the usage of migraine drugs and lack of awareness in people regarding migraine drugs, particularly in women, are expected to hinder the market. Lengthy and time-consuming FDA approval process for migraine drugs and the shortage of neurosurgeons and physicians are significant restraints for the market growth.

This research report on the North America Migraine Drugs Market has been segmented and sub-segmented into the following categories:

• By Treatment: Preventive and Absorptive
• By Therapeutic Class: Triptants, Ergots, and Others
• By Country: The United States, Canada, and Rest of North America

Regionally, the North America migraine drug market was the dominating region in the global market in 2019. It is predicted that North American will be continuing its dominance between 2020 to 2025. According to the American Migraine Association, over 36 million people had migraines in 2015.

The migraine drug market in the United States is expected to dominate the North American market during the forecast period and held 65% of the share in 2017. The introduction of Calcitonin gene-related (CGRP) based therapies, growing acquisition of new treatments, and large aided population are expected to drive the market in the United States. Increasing intake of unhealthy food and increasing incidence of chronic diseases, presence of key players, and escalating concentration on precision medicine in the United States are further estimated to favor the market to grow in the forecast timeframe. 

The Canadian market is expected to showcase a promising CAGR due to the increasing prevalence of migraine 

Companies playing a dominant role in the North America Migraine Drug Market profiled in this report are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories. The other prominent vendors the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor, RedHill, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan, and Zogenix.